Curcumin and COVID-19: A Systematic Review of Clinical Trials
In this systematic review, 8 studies that examined use of curcumin (specifically nano-curcumin formulations) in people with COVID-19, with a total of 569 participants, were included for review. Nano-curcumin supplementation had no significant effect on CRP, hs-CRP, TNF-α, or IL-6 levels compared to placebo. However, IL-6 and IL-1β expression were significantly reduced by nano-curcumin. Compared to controls, the duration of hospitalization as well as mortality rate were significantly lower for those receiving nano-curcumin. Lymphocyte count was significantly increased with nano-curcumin as well.
Nano-curcumin also had favorable effects on clinical outcomes and symptoms, including O2 sat, sputum, chest pain, wheeze, dyspnea, fever, cough, chills, myalgia, and olfactory/taste disturbances. Nano-curcumin was well tolerated, with no major adverse effects.
Citation:
Shojaei M, Foshati S, Abdi M, Askari G, Sukhorukov VN, Bagherniya M, Sahebkar A. The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials. Phytother Res. 2023 Feb 17. doi: 10.1002/ptr.7778.
Link: